CN110117595B - 一种特异性结合pdl1的核酸适配体及其应用 - Google Patents
一种特异性结合pdl1的核酸适配体及其应用 Download PDFInfo
- Publication number
- CN110117595B CN110117595B CN201910407453.9A CN201910407453A CN110117595B CN 110117595 B CN110117595 B CN 110117595B CN 201910407453 A CN201910407453 A CN 201910407453A CN 110117595 B CN110117595 B CN 110117595B
- Authority
- CN
- China
- Prior art keywords
- aptamer
- pdl1
- cells
- tumor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种特异性结合癌细胞表面PDL1蛋白分子的核酸适配体,其序列如SEQ ID NO:1所示及其在肿瘤检测方面和在促进T细胞对肿瘤细胞杀伤的应用;本发明的核酸适配体能与肿瘤细胞表面PDL1蛋白特异性结合,亲和力高,单链寡核苷酸只识别与其互补的空间结构,几乎可以完全避免非特异性结合;本发明的核酸适配体合成成本低,采用SELEX筛选技术可以实现自动化,并且筛选出的核酸适配体经化学合成纯度高,准确度与重复性好。
Description
技术领域
本发明涉及生物技术领域,具体说是一种特异性结合PDL1的核酸适配体及其应用。
背景技术
程序性死亡受体1(programmed death 1,PD-1)是T细胞表面的跨膜受体,参与细胞的凋亡,PD1与PDL1(PD-1ligand1,PD-L1)和PDL2(PD-1ligand2,PD-L2)配体相互作用抑制T细胞的增殖,PDL1、DPL2主要表达在抗原递呈细胞中(如DC细胞、巨噬细胞)。研究发现,多种肿瘤细胞高表达PDL1,如多发性骨髓瘤、黑色素瘤、非小细胞肺癌、卵巢癌、肾癌等。肿瘤细胞在多种因子作用下高表达PDL1,与T细胞表面的PD1分子相互作用,抑制T细胞的活化与增殖,进而引起免疫逃逸现象。同时诸多研究证实,癌组织内PDL1蛋白的表达水平的升高明显降低病人的预后与存活率,因此有针对的阻断PD1/PDL1信号通路,能有效增强T细胞对肿瘤细胞的杀伤和肿瘤的治疗效果。
核酸适配体(Aptamer)是一段DNA,通常是利用体外筛选技术——指数富集的配体***进化技术(Systematic evolution of ligands by exponential enrichment,SELEX),从核酸分子文库中得到的寡核苷酸片段。核酸适配体能与多种目标物质高特异性、高选择性地结合,因此被广泛应用于生物传感器领域,当核酸适配体与目标物质发生特异性结合时,核酸适配体自身的构型会随之发生变化。传统的抗原抗体反应灵敏度和特异性均较好,酶联免疫反应在各种生物分子的探测中发挥着举足轻重的作用,但是蛋白质作为探针分子,容易受pH、温度等环境因素影响而变性且合成价格昂贵,适配体由DNA或RNA构成(主要是DNA),比蛋白质体积更小,稳定性更好,在未来,适配体有望取代酶联免疫反应,成为各种化学分子探测的有力武器。
发明内容
为解决上述问题,本发明的目的是提供一种特异性结合PDL1的核酸适配体及其应用。
本发明为实现上述目的,通过以下技术方案实现:
一种特异性结合癌细胞表面PDL1蛋白分子的核酸适配体,其序列如SEQ ID NO:1所示。
本发明还包括一种特异性结合癌细胞表面PDL1蛋白分子的核酸适配体在肿瘤检测方面的应用。
本发明还包括一种特异性结合癌细胞表面PDL1蛋白分子的核酸适配体在促进T细胞对肿瘤细胞杀伤的应用。
优选的应用,所述肿瘤为肺癌、多发性骨髓瘤、肾癌和黑色素瘤。
本发明相比现有技术具有以下优点:
本发明的核酸适配体能与肿瘤细胞表面PDL1蛋白特异性结合,亲和力高,单链寡核苷酸只识别与其互补的空间结构,几乎可以完全避免非特异性结合;本发明的核酸适配体合成成本低,采用SELEX筛选技术可以实现自动化,并且筛选出的核酸适配体经化学合成纯度高,准确度与重复性好。
附图说明
图1为特异性结合PDL1的核酸适配体制备过程的流程示意图;
图2为流式细胞仪检测各组细胞中PE荧光的强度的示意图;
图3为2号aptamer和无意aptamer分别与人多发性骨髓瘤细胞系RPMI8226和L363细胞孵育的荧光强度示意图;
图4为2号aptamer与RPMI8226细胞和L363细胞的KD值图;
图5为显微镜下2号aptamer和对照组aptamer与肾癌组织切片的识别和结合的结果示意图;
图6为显微镜下2号aptamer对肺癌细胞和正常肺细胞的表面PDL1蛋白的识别与结合的荧光结果示意图。
具体实施方式
本发明的目的是提供一种特异性结合PDL1的核酸适配体及其应用,通过以下技术方案实现:
一种特异性结合癌细胞表面PDL1蛋白分子的核酸适配体,其序列如SEQ ID NO:1所示。
本发明还公开了特异性结合癌细胞表面PDL1蛋白分子的核酸适配体在肿瘤检测方面的应用。
本发明还公开了特异性结合癌细胞表面PDL1蛋白分子的核酸适配体在促进T细胞对肿瘤细胞杀伤的应用。
优选的应用,所述肿瘤为肺癌、多发性骨髓瘤、肾癌和黑色素瘤,多发性骨髓瘤细胞系如RPMI8226、L363等。
以下结合具体实施例来对本发明作进一步的描述。
实施例1
一种特异性结合癌细胞表面PDL1蛋白分子的核酸适配体,其序列如SEQ ID NO:1所示。
实施例2
1、如图1所示的流程示意图,通过人工合成,建立随机寡核苷酸库,以PDL1蛋白为靶蛋白,选择性分离出同靶蛋白特异性结合的核酸适配体(aptamer)。
2、RPMI8226属于PDL1阳性高表达细胞,L363属于阴性低表达细胞。采用消减SELEX筛选出与PDL1蛋白特异性结合的aptamer。消减SELEX筛选三个与PDL1蛋白特异性结合的aptamer,同时设计了一个无意aptamer;
无意核酸适配体aptamer序列SEQ ID NO:2:
acgggccaaatactcattcggtacgaccatgcgaccactgcttacgt;
1号核酸适配体aptamer序列SEQ ID NO:3:
acgggcctcacacatcaataattagccactgcctagagcgttcgcgt;
2号核酸适配体aptamer序列SEQ ID NO:1:
acgggcctctctgaacaaaggtattagacatcatgcgtgcccccagt;
3号核酸适配体aptamer序列SEQ ID NO:4:
acgggcacacatcactcgctgcccgtaagattattgaccaatcacgt;
消减SELEX筛选采用以下步骤:
⑴浓度10pmol/μL的随机寡核苷酸文库35微升加入到200微升选择性缓冲液内(Tris.HCl 50mM;KCl 5mM;NaCl 100mM;MgCl 1mM;pH7.4),加热99℃5min变性,立即置于0℃5min(加入过量的酵母tRNA与BSA降低背景);
⑵将上述溶液与1*105个RPMI8226细胞37℃混匀孵育30min,1000rpm离心5min,弃去上清,沉淀用选择性缓冲液溶解混匀,再1000rpm离心,如此反复6次;
⑶沉淀加入双蒸水,100℃加热10min,10000rpm离心5min,上清抽提核苷酸,20微升缓冲液溶解;
⑷将抽提出的核苷酸作为模板进行PCR扩增:
①反应体系:模板20微升;10*缓冲液10微升;dNTPs5微升;MgCL23.5微升;上下游引物各5微升;Taq酶5微升;加水至50微升;
②反应条件:94℃3min,20个循环:94℃50s,55℃50s,72℃50s,最后72℃5min。
⑸PCR产物经苯酚:氯仿抽提出核酸,溶解于缓冲液中;
⑹再按照⑴~⑸步骤反复10轮左右,筛选出适量核酸适配体,再经反筛选进一步排除非特异性结合;
⑺经10轮筛选后的寡核苷酸文库,以L363细胞作为负性靶细胞进行反筛选,PCR产物99℃加热5min然后立即置于0℃5min;
⑻先将1*105个L363细胞离心收集,弃掉上清,用上述液体与细胞沉淀在37℃混匀孵育30min,1000rpm离心5min,收集上清,继续用1*105个L363细胞37℃孵育30min,再1000rpm离心5min,收集上清,如此反复5次;
⑼将最后筛选出的核苷酸,用上下游测序引物扩增成dsDNA,回收纯化后连接到T载体,经筛选后随机挑选进行测序;
10)最终经11轮正筛与6轮反筛,确定三个aptamer以及合成了一个无意aptamer;
3、研究发现,多发性骨髓瘤细胞系RPMI8226在IFN-γ的刺激下,细胞表面的PDL1蛋白表达明显增加。基于此,我们来检测筛选出的aptamer对人PDL1蛋白的结合情况并将其与PDL1抗体相对照。将RPMI8226细胞系传代到一个二十四孔板中的十个孔,每孔3*105个细胞,随机选取五个孔,每孔加入1000IU的IFN-γ,37℃、5%CO2培养箱中孵育24h;
4、24h后,取出其中八个孔中的细胞(4个无刺激、4个IFN-γ刺激24h)分别加入已灭菌的1.5ml EP管内,1000rpm离心15min,弃掉上清,预冷的PBS洗涤一次,离心弃上清,将其和PE标记的不同aptamer(无意aptamer与1-3号aptamer)在100微升预冷PBS溶液中避光孵育20分钟,同时将剩余两个孔内的细胞收集并将它们分别与5微升的PE-PDL1抗体避光孵育20分钟。孵育完毕后,离心,弃上清,用200微升预冷PBS洗涤一次,再离心弃上清,加入600微升的预冷PBS,重悬细胞,流式细胞仪检测各组细胞中PE荧光的强度,如图2所示,已有研究报道RPMI8226在IFN-γ的刺激下,细胞表面PDL1蛋白的表达显著升高,PE-PDL1抗体与细胞共孵育也证实这一结果。我们还发现PE标记的2号aptamer显示的结果与PDL1抗体的结果最相近,提示我们2号aptamer与PDL1蛋白的结合与PDL1抗体几无差异。(*:与空白对照组相比p<0.05,**:与空白对照组相比p<0.01)。
5、选取人多发性骨髓瘤细胞系RPMI8226(PDL1高表达)和L363(PDL1低表达)分别培养在含有10%FBS的1640培养基内,37℃,5%CO2培养箱中培养。细胞在对数生长期时候,收集1*105的RPMI8226与L363,将其和一系列不同浓度(0、5、25、125、250、500、1000nM)FAM标记的2号aptamer在100微升结合缓冲液(含有0.5%BSA的PBS溶液)中37℃反应60分钟,PBS清洗两次,细胞上流式细胞仪检测:同等长度的无意aptamer作为随机对照。图3结果显示,1000nM的2号aptamer与PDL1高表达的RPMI8226细胞孵育的荧光强度明显强于随机对照组,而2号aptamer与低表达的L363细胞孵育的荧光强度与随机对照组几无差异。表明2号aptamer与PDL1高表达细胞结合性强。利用GraphPad Prism5软件计算2号aptamer与RPMI8226细胞和L363细胞的KD值,分析结果如图4所示,2号aptamer与RPMI8226细胞的KD值是68.45±5.36,L363细胞的KD值为189.35±51.34,2号aptamer与RPMI8226细胞的结合能力强于L363细胞;
6、采用临床肾癌病理切片来验证2号aptamer对癌组织表面PDL1蛋白的识别与结合。将石蜡包埋的正常肾组织与肾癌组织切片于65℃烤箱中烘烤1h,切片浸于二甲苯中脱蜡两次,每次10min;浸入无水乙醇两次,每次5min;切片依次经过梯度乙醇(90%、85%、70%乙醇各一次,每次3min),最后浸入PBS;微波修复法对切片进行抗原修复,待冷却至室温,使用PBS洗两次;随后使用山羊血清室温封闭1h;去除封闭液,分别加入HRP标记的2号aptamer于4℃孵育1h;洗涤缓冲液洗3次,每次5min;随后加入辣根酶标记链霉卵白素工作液室温孵育30min;经洗涤后,加入DAB显色液显色(镜下控制时间)。梯度酒精脱水,二甲苯透明,中性树胶封片,显微镜下观察。结果如图5所示,2号aptamer能够特异性识别切片肾癌细胞表面PDL1蛋白,但与正常的肾脏呈现较弱结合,对照组aptamer与肾癌组织内PDL1蛋白结合也比较弱,从而2号aptamer在临床上可用于肾癌细胞表面PDL1蛋白的检测和诊断。
7、采用临床非小细胞肺癌病理切片进一步验证2号aptamer与肺癌细胞表面PDL1蛋白的识别与结合。将石蜡包埋的正常肺与非小细胞肺癌组织病理切片于60℃烤箱中烘烤1.5h,切片浸于二甲苯中脱蜡两次,每次10-20min;浸入无水乙醇两次,每次5-10min;切片依次经过梯度乙醇(90%、85%、70%乙醇各一次,每次3-5min),最后浸入PBS;微波修复法对切片进行抗原修复,待冷却至室温,使用PBS洗两次;加入Cy5标记的2号aptamer于4℃孵育1-2小时,PBS洗两次,每次3-5min,防荧光淬灭封片剂封片,荧光显微镜下观察。结果如图6所示,非小细胞肺癌组织中,红色荧光强度明显高于正常肺组织,提示我们2号aptamer能识别与结合非小细胞肺癌组织表面的PDL1蛋白。
序列表
<110> 山东昂科诺生物科技有限公司
<120> 一种特异性结合PDL1 的核酸适配体及其应用
<141> 2019-05-10
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 47
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
acgggcctct ctgaacaaag gtattagaca tcatgcgtgc ccccagt 47
<210> 2
<211> 47
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
acgggccaaa tactcattcg gtacgaccat gcgaccactg cttacgt 47
<210> 3
<211> 47
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
acgggcctca cacatcaata attagccact gcctagagcg ttcgcgt 47
<210> 4
<211> 47
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
acgggcacac atcactcgct gcccgtaaga ttattgacca atcacgt 47
Claims (4)
1.一种特异性结合癌细胞表面PDL1蛋白分子的核酸适配体,其特征在于:其序列如SEQID NO:1所示。
2.权利要求1所述的特异性结合癌细胞表面PDL1蛋白分子的核酸适配体在制备肿瘤检测试剂中的应用。
3.权利要求1所述的特异性结合癌细胞表面PDL1蛋白分子的核酸适配体在制备促进T细胞对肿瘤细胞杀伤试剂中的应用。
4.根据权利要求2或3所述的应用,其特征在于:所述肿瘤为肺癌、多发性骨髓瘤、肾癌或黑色素瘤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910407453.9A CN110117595B (zh) | 2019-05-15 | 2019-05-15 | 一种特异性结合pdl1的核酸适配体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910407453.9A CN110117595B (zh) | 2019-05-15 | 2019-05-15 | 一种特异性结合pdl1的核酸适配体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110117595A CN110117595A (zh) | 2019-08-13 |
CN110117595B true CN110117595B (zh) | 2020-11-10 |
Family
ID=67522577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910407453.9A Active CN110117595B (zh) | 2019-05-15 | 2019-05-15 | 一种特异性结合pdl1的核酸适配体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110117595B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4083210A1 (en) * | 2019-12-27 | 2022-11-02 | Interoligo Corporation | Anti-cancer immunotherapeutic composition for treating cancer |
CN113699157B (zh) * | 2020-05-20 | 2023-03-31 | 中国科学院苏州纳米技术与纳米仿生研究所 | Pd-l1核酸适配体、其筛选方法及应用 |
CN114127293B (zh) * | 2020-06-30 | 2023-08-04 | 首都师范大学 | 一种体外筛选pd-l1的dna核酸适配体的方法及其在癌症诊断中的应用 |
CN113667672A (zh) * | 2021-08-09 | 2021-11-19 | 优葆优保健康科技(宁波)有限公司 | 一种靶向pd-l1胞外片段的dna适配体 |
CN116875604A (zh) * | 2022-10-19 | 2023-10-13 | 聊城市人民医院 | 一种用于pd-l1阳性细胞检测的dna适配体及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3344772B1 (en) * | 2015-09-01 | 2020-08-26 | Academia Sinica | Antagonistic pdl1 aptamers and their applications in cancer therapy |
CN107794268B (zh) * | 2017-03-14 | 2021-03-26 | 湖南大学 | 检测人pdl1蛋白的核酸适体及其在制备检测制剂中的应用 |
CN107794267B (zh) * | 2017-03-14 | 2021-03-26 | 湖南大学 | 一种靶向pd1-pdl1的双特异性核酸适体及其衍生物 |
CN109387499B (zh) * | 2017-08-08 | 2021-03-26 | 华东师范大学 | 一种pd-l1探针及其制备方法和应用 |
CN108929874B (zh) * | 2018-07-11 | 2021-12-14 | 安徽省昂普拓迈生物科技有限责任公司 | 一种特异性结合高表达pdl1蛋白的细胞的核酸适配体及其应用 |
-
2019
- 2019-05-15 CN CN201910407453.9A patent/CN110117595B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110117595A (zh) | 2019-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110117595B (zh) | 一种特异性结合pdl1的核酸适配体及其应用 | |
Sole et al. | The circulating transcriptome as a source of cancer liquid biopsy biomarkers | |
Berezovski et al. | Aptamer-facilitated biomarker discovery (AptaBiD) | |
JP2019535307A (ja) | エキソソーム結合型核酸の配列決定および分析 | |
JP2024009855A (ja) | がんを検出するための非コードrna | |
CN110643611B (zh) | 一种核酸适配体及其构建方法和其在检测石斑鱼虹彩病毒中的应用 | |
EP4127221A1 (en) | Single cell genetic analysis | |
CN106957906B (zh) | 一种应用于高通量测序检测t细胞白血病微小残留病的引物组合及试剂盒 | |
CN107090503B (zh) | 探针组合物、基因捕获芯片、试剂盒及其应用 | |
CN111073892A (zh) | 一种识别石斑鱼虹彩病毒感染细胞的核酸适配体及其构建方法和应用 | |
CN111073891A (zh) | 一种检测石斑鱼虹彩病毒的核酸适配体及其构建方法和应用 | |
Afshar et al. | Transcriptional drifts associated with environmental changes in endothelial cells | |
CN113699156B (zh) | Pd-1核酸适配体、其筛选方法及应用 | |
JP6451632B2 (ja) | 異種核酸プローブを用いた修飾核酸塩基の測定方法およびキット | |
Wang et al. | Identification of a novel molecular probe for recognition of human osteosarcoma cell using the cell-SELEX method | |
JP6451634B2 (ja) | 吸収剤ポリヌクレオチドを用いた修飾核酸塩基の測定方法およびそのキット | |
KR102539423B1 (ko) | 엑소좀 유래 rna를 이용한 비침습적 대장암 진단 및 분석법 | |
Kaur et al. | Single-Cell Genomics: Technology and Applications | |
CN111118014B (zh) | 一种抗虹彩病毒的核酸适配体及其构建方法和应用 | |
CN113699157B (zh) | Pd-l1核酸适配体、其筛选方法及应用 | |
CN114317544A (zh) | 特异性结合cd133的核酸适配体、其筛选方法及应用 | |
CN113564172A (zh) | 一种液体活检肿瘤细胞dna适配体 | |
CN114574498B (zh) | 一种靶向肿瘤相关成纤维细胞的核酸适配体及其应用 | |
CN111363749A (zh) | 一种用于检测中华鳖虹彩病毒的核酸适配体及其构建方法和应用 | |
CN115074365B (zh) | 靶向GATM基因的sgRNA及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |